MedTrace Logo

Poor Ovarian Stimulation Response in In Vitro Fertilization (IVF) Program

NCT02640976 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 216

Last updated 2015-12-29

No results posted yet for this study

Summary

The aim of this study is to assess the role of AMH in prediction of poor ovarian response as well as the relation between ESR2 (+1730G\>A) (rs4986938), FSHR p.Thr307Ala (c.919A\>G, rs6165) and FSHR p.Asn680Ser (c.2039A\>G, rs6166) SNPs and the poor response in Egyptian women undergoing IVF procedure. Discovering the genetic variants associated with ovarian response is an important step towards individualized pharmacogenetic protocols of ovarian stimulation.

Conditions

Interventions

DRUG

Human menopausal gonadotrophin (HMG)

\[Merional® 75 IU ampoules, IBSA institut\]

DRUG

GnRH antagonist Cetrorelix

\[Cetrotide® 0.25 mg syringes, Merck Serono\]

DRUG

Human chorionic gonadotrophin (hCG)

\[Choriomon® 5000 IU ampoules, IBSA institut\]

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2015-06-30
Completion
2015-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02640976 on ClinicalTrials.gov